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ABSTRACT
Aim To identify modes of venous thromboembolism (VTE) 
prophylaxis in patients undergoing elective major orthopaedic sur-
gery (total hip or knee arthroplasty, THA/TKA) at a single univer-
sity-associated hospital in Croatia.
Methods A retrospective analysis of consecutive patients subjec-
ted to THA or TKA over a two-year period (2014-2015) with a 
focus on anticoagulation during the first 15 post-surgical days (pe-
riod of highest VTE risk).
Results  Of 603 identified patients three (0.5%) were not anticoa-
gulated (haemophilia) and others received perioperative doses of 
low molecular weight heparins (LMWH). Overall, 228 (37.8%) 
patients received prophylaxis not involving warfarin, and 372 con-
tinued with short-term LMWH with switching to warfarin. They 
contributed a total of 1218 international normalized ratio (INR) 
values (median=3, range=1-8). These were consistently below the 
target INR range across the observed period. Between post-surgi-
cal days 6 and 15 (after the initial titration), 438 values were taken 
in patients treated with LMWH+warfarin and 92.7% were below, 
and only 6.8% within the target range; 580 values were taken in 
patients already switched to warfarin, 74% were below and only 
25% within the range.
Conclusion The prevailing mode of VTE prophylaxis was in a 
clear contrast to (then) actual professional guidelines, with ina-
dequate monitoring and poor anticoagulation. There is no reason 
to expect a substantially different situation at other institutions 
across the country. The prevailing practice of VTE prophylaxis 
in major orthopaedic surgery in Croatia should be promptly aban-
doned and up-dated in agreement with the current state of the art.
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INTRODUCTION
Elective total hip (THA) and knee arthroplasty 
(TKA) are highly successful procedures that con-
vey great improvements in functional ability and 
quality of life in patients suffering a variety of pat-
hological hip/knee conditions. Both surgeries have 
a successful and long-standing history in Croatia 
(1). However, both procedures are associated with 
an increased risk of post-surgical venous throm-
boembolic incidents (VTE) – deep venous throm-
bosis or pulmonary embolism. In the 1970s, the 
estimated risk of such events was in the range of 
20-25% but introduction of thromboprophylaxis, 
improvement of surgical techniques and post-sur-
gical management (e.g., early ambulation) have 
greatly reduced their occurrence (2). As estima-
ted by the American College of Chest Physicians 
(ACCP), the critical period for the occurrence of 
VTE lasts for 30-35 post-surgical days and a con-
temporary risk of symptomatic VTE associated 
with elective THA/TKA without prophylaxis is 
estimated at 2.9% over the first 15 post-surgical 
days and up to 4.6% during the 30-35 days (2). 
While there are different mechanical and pharma-
cological means of thromboprophylaxis, a thoro-
ugh systematic review conducted by ACCP de-
monstrated that pharmacological means should be 
preferred except when explicitly contraindicated 
(2). Based on a comprehensive evaluation of clini-
cal trial data of individual pharmacological means 
vs. no treatment, mechanical methods or vs. each 
other, which assessed the risk of VTE and the risk 
of relevant bleedings (i.e., major or non-major cli-
nically relevant), ACCP also suggested that low-
dose acetylsalicylic acid (alone or combined with 
mechanical means) and unfractionated heparin 
should not be used in this setting, emphasized the 
role of low molecular weight heparins (LMWH) 
particularly in comparison to vitamin K antago-
nists and depicted the emerging role of the new 
orally active anticoagulants (NOACs) (2).
There are no formal surveys on thrombop-
hrophylaxis in this setting in Croatia, but an ad hoc 
survey among the members of the Croatian Ortho-
paedic Society during the 2016 annual assembly 
confirmed the common knowledge - the prevailing 
mode of thrombophrophylaxis related to THA/
TKA consists of a short-term peri-operative (up 
to several days after the surgery) use of LMWH 
(first dose before the surgery) with concomitant 
introduction of vitamin K antagonists (almost 
exclusively warfarin) and subsequent continuation 
of treatment with warfarin, and is driven by the po-
licy of the Croatian Health Insurance fund which 
reimburses only the “in-hospital” use of LMWH. 
However, ACCP has demonstrated (2) that even 
under the conditions of controlled clinical trials 
with extremely high rate of appropriate warfarin 
use (time in therapeutic range, TTR), i.e. with in-
ternational normalized ratio (INR) values between 
2.0 and 3.0 (targeted value 2.5%), >60%), this stra-
tegy was inferior to the exclusive use of LMWH as 
it resulted in several excess cases of VTE and 40 
excess cases of major bleeding/1000 treated. 
An observational study in the USA (2009-2011) 
included 596 THA/TKA patients treated with 
such an approach, who received warfarin over 
10-35 days and were monitored through speciali-
zed anticoagulation clinics at two university hos-
pitals (3). The average TTR was 36% and median 
time to the first INR within the target range was 
12-13 days. A similar study (4) embraced 3313 
THA/TKA patients (2005-2009). The median 
number of determined INR values over the 28-
35 post-surgical days per patient was 5 (excluded 
were the initial 5 days of “early titration”). The 
average TTR was 28%, only 33% of the deter-
mined INR values were within the range, avera-
ge proportion of time with INR <2.0 was 64%, 
and patients who did not experience a single INR 
value within the range had 5.3 times higher risk 
of symptomatic VTE (incidence of VTE in the 
cohort was 3.3%). Overall, data suggest that even 
with stringent monitoring and careful titration, 
warfarin does not seem to achieve the desired le-
vel of anticoagulant activity during the period of 
the highest VTE risk. 
Warfarin-based anticoagulation is specific in that 
it successfulness greatly depends on close moni-
toring. There are no specialized anticoagulation 
clinics in Croatia and no structured monitoring 
systems (e.g., registries) of long-term anticoagu-
lation e.g. in stroke prevention or VTE treatment/
prophylaxis. A recent study demonstrated a poor 
practice of warfarin-based anticoagulation in 
Croatian patients with atrial fibrillation schedu-
led for direct current cardioversion (5). The pre-
sent analysis aimed to evaluate anticoagulation 
adequacy in elective major orthopaedic surgery 
in a specialized Croatian hospital.
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PATIENTS AND METHODS
Study design
This retrospective analysis refers to a 2-year pe-
riod (January 1 2014 – December 31 2015) at 
the Department of Trauma Surgery,  University 
Hospital Centre “Sestre Milosrdnice”, Zagreb, 
Croatia in order to identify modes of venous 
thromboembolism (VTE) prophylaxis in patients 
undergoing elective major orthopaedic surgery 
(total hip or knee arthroplasty, THA/TKA). 
The study was approved by the Ethics Com-
mittee of the University Hospital Centre “Sestre 
Milosrdnice”, Zagreb, Croatia. 
Eligible for inclusion were consecutive patients 
who underwent primary elective THA/TKA. 
Methods
Two researches independently searched the hos-
pital electronic database system for the specific 
procedure codes matched with the unique patient 
identification numbers. Results were mutually re-
checked and verified through hard-copy archives. 
Demographic, comorbidity, co-medication data 
and data on peri-operative anticoagulation tre-
atment, as well as laboratory data on coagulation 
monitoring tests were extracted for a period of 15 
post-surgical days (Table 1). We restricted the ob-
servational period to the first 15 post-surgical days 
as this is the period of the highest risk for VTE.  
RESULTS
A total of 603 patients were enrolled, mostly su-
bjected to THA, 434 (72%) (Table 1). 
Apart from three patients with haemophilia, 
all underwent anticoagulation and received a 
pre-surgical and a post-surgical low molecular 
weight heparin (LMWH) dose (Figure 1). For 
228 (37.8%) patients anticoagulation did not 
include warfarin, however for 120 (19.9%) pa-
tients only short-term LMWH treatment could 
be verified without any information about further 
prophylaxis. Overall 103 (17.1%) patients re-
ceived LMWH prophylaxis during the observed 
period, and sporadic patients were treated with 
new orally active anticoagulants (NOACs) or 
LMWH, and acetylsalicylic acid. The majority of 
the patients, 372 (61.5%) underwent prophylaxis 
with LMWH switching to warfarin and contribu-
ted a total of 1218 INR values (median=3, range 
1-8 per patient). Almost 1/3 one third of the pa-
tients, 113 (30.4%) contributed only 1 or 2 INR 
values over the observed 15 days (Figure 1). 
Characteristic No (%) of patients
Total 603
Total hip / knee arthroplasty 434 (72) / 169
Age (range, years) 69 (20-97)
Males 273 (45.3)
Previous use of antiplatelet 76 (12.6)
Previous use of anticoagulants 33 (5.4)
History of pulmonary embolism 1 (0.2)
History of deep venous thrombosis 20 (3.3)
History of myocardial infarction or angina 23 (3.8)
History of transitory ischemic attack or stroke 10 (1.7)
Atrial fibrillation or flutter 25 (4.1)
Chronic heart failure 71 (11.8)
Venous insufficiency 50 (8.3)
Diabetes mellitus 71 (11.8)
Thrombocytopenia 6 (1.0)
Haemophilia 3 (0.5)
Table 1. Characteristics of patients who underwent elective 
major orthopaedic surgery (total hip or knee arthroplasty) Figure 1. Patient eligibility diagram. Histogram depicts distribu-
tion of patients (absolute counts and cumulative relative distri-
bution) across the number of contributed international normal-
ized ratio (INR) values
ASA, acetylsalicylic acid; LMWH, low molecular weight heparin; 
NOACs, new orally active anticoagulants 
Regardless of the treatment under which INR 
values were provided, over time they were con-
sistently below the target INR range. Conside-
ring the period between days 6-15 (after initial 
titration would be expected to be accomplished), 
92.7% out of 439 values taken in patients under 
LMWH + warfarin treatment were below the 
target as well as 74% out of 580 values taken in 
247
patients already switched to warfarin, with only 
25% within the target range (Figure 2). 
DISCUSSION
Although conducted at a single centre and thus 
not representative for the entire country, the pre-
sent results confirmed three expectations. First, 
the initial use of LMWH with switching to war-
farin was the most predominant practice. Second, 
in the setting of major orthopaedic surgery there 
was no “centralized structured” monitoring of 
successfulness of anticoagulation: at the insti-
tution at which the surgery was indicated and 
performed, and at which the anticoagulation was 
initiated, only sparse data on a laboratory mar-
ker (i.e., INR in patients treated with warfarin) 
of its successfulness were recorded (30.4% pa-
tients contributed only 1 or 2 INR values over 
the observed period) and there were practically 
no records on the overall outcome (i.e., records 
of VTE/bleedings during the first month post-
surgery). Third, although TTR could not be de-
termined due to paucity of the international nor-
malized ratio (INR) values, data on percentage of 
values within the target INR range, particularly 
those taken between days 6 and 15 (after the “ini-
tial titration” period) strongly indicate the failu-
re of the procedure to achieve a known strongly 
predictive (for clinical outcomes) laboratory goal 
during the period of the highest VTE risk. While 
patients treated with both LMWH and warfarin 
could be considered “protected” (on the account 
of LMWH), the fact that 92.7% of their INR va-
lues were below the target clearly demonstrated 
that they were not fit to continue only warfarin 
treatment. On the other hand, the fact that 74% of 
the values taken in patients treated with warfarin 
were only below the target clearly documented 
excessive “under-protection” from the VTE risk.
In 2012 the American College of Chest Physicians 
(ACCP) clearly recommended the preference of 
pharmacological over mechanical (various forms) 
thromboprophylaxis in major orthopaedic surgery 
(except where the former were explicitly contra-
indicated) and strongly advised (based on rando-
mized controlled trial data) against the use of vi-
tamin K antagonists (e.g., warfarin) due to inferior 
balance between the VTE and bleeding risks as 
compared to LMWH (2). Observational data with 
stringent anticoagulation monitoring (3,4) demon-
strated that warfarin inherently did not seem to be 
appropriate for a setting in which a rapid onset of 
a relative short anticoagulation is needed (30 days 
overall, with the highest risk over first 15 post-sur-
gical days): median time to target INR has been 
estimated to equal the period of the highest risk 
(12-13 days) (3), time in therapeutic range over 
the first 30 post-surgical days has been repeated-
ly reported to be around 30% (3,4) with around 
30% of INR values within the range (4). The pre-
sent data are in line with these observations and 
actually indicate that the situation is even worse 
when there is no structured monitoring of the war-
farin effect. In one large cohort (3313 THA/TKA 
patients) treated with warfarin between post-sur-
Figure 2. International normalized ratio (INR) values in the subset of patients anticoagulated by the “LMWH-to-warfarin” treatment. 
Shaded areas indicate the target INR range. Individual values (circles) across the observed 15 days by treatment (left) and individual 
values at days 1-5 and 6-15 by treatment (right) with the absolute number (percentage) of values below, within and above the range
LMWH, low molecular weight heparin; Warf, warfarin
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gical days 5-30 (4), the rate of symptomatic VTE 
was 3.3% - almost as if no anticoagulation was 
installed: the best estimate of the contemporary 
VTE risk without thromboprophylaxis is 4.6% 
(cumulatively over 30-35 days) and appropriate 
prophylaxis is expected to reduce it by 65-70%, 
relatively (2). Clearly, it is time to completely 
abandon the practice of warfarin use in this setting. 
In 2012, ACCP recommended the use of LMWH 
(during the entire period of the increased risk) (2). 
In the meantime, NOACs have emerged as a new 
valid option: three have gained regulatory appro-
val in this setting (dabigatran, rivaroxaban, apixa-
ban) and have demonstrated a comparable VTE/
bleeding risks balance as compared to LMWH 
(6,7) with a convenience of simpler oral dosing. 
Nowadays, therefore, the most adequate options 
for VTE prophylaxis in major orthopaedic surgery 
should be identified among LMWH and NOACs 
and should take into account not only populati-
on estimates of their efficacy and safety, but also 
individual pharmacological characteristics (e.g., 
pharmacokinetics, dependence on renal function) 
and co-morbidity (e.g. existing long-term antico-
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professional guidelines, with inadequate monito-
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other institutions across the country. The preva-
iling practice of VTE prophylaxis in major ort-
hopaedic surgery in Croatia should be promptly 
abandoned and up-dated in agreement with the 
current state of the art.
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SAŽETAK
Cilj Identificirati modalitete prevencije venskog tromboembolizma (VTE) u bolesnika podvrgnutih 
elektivnim velikim ortopedskim zahvatima (totalna artroplastika kuka ili koljena) u jednom sveučiliš-
nom medicinskom centru u Hrvatskoj. 
Metode Retrospektivna analiza podataka o uzastopnim bolesnicima, podvrgnutim totalnoj artroplastici 
kuka ili koljena, tijekom dvije godine (2014-2015), s fokusom na antikoagulacijsko liječenje tijekom 
prvih 15 postoperativnih dana (razdoblje najvišeg rizika za VTE).
Rezultati Od ukupno 603 bolesnika, troje (0.5%) nisu bili antikoagulirani (hemofilija), dok su ostali 
primili preoperativne doze niskomolekularnog heparina (LMWH). U ukupno 228 (37.8%) bolesnika 
antikoagulacijski tretman nije uključivao varfarin, dok su 372 bolesnika tretirana kratkotrajnom pri-
mjenom LMWH-a s prijelazom na varfarin. Tijekom promatranog razdoblja ukupno je izmjereno 1.218 
vrijednosti internacionalnog normaliziranog omjera (INR) (medijan=3, raspon= 1-8, po bolesniku). Vri-
jednosti su konzistentno bile ispod terapijskog INR-raspona. U razdoblju između šestog i petnaestog 
postoperativnog dana (nakon početne titracije), ukupno je izmjereno 438 INR-vrijednosti u bolesnika 
koji su primali i LMWH i varfarin, te je 92.7% njih bilo ispod terapijskog raspona, a samo 6.8% vrijed-
nosti bilo je u terapijskom rasponu. Istodobno, izmjereno je ukupno 580 INR-vrijednosti u bolesnika 
koji su već bili prebačeni na varfarin – 74% vrijednosti bilo je ispod, a samo 25% vrijednosti bilo je u 
terapijskom rasponu.
Zaključak Opaženi dominantni oblik VTE profilakse u izravnoj je suprotnosti s profesionalnim smjer-
nicama, s neadekvatnim nadzorom i nedostatnom antikoagulacijom. Nema razloga očekivati da je sta-
nje bitno drugačije u ostalim institucijama u zemlji. Taj predominantni oblik VTE profilakse u velikim 
ortopedskim zahvatima u Hrvatskoj treba što prije napustiti i uvesti postupke u skladu s trenutno važe-
ćim standardima dobre kliničke prakse.
Ključne riječi kuk, koljeno, artroplastika, venski tromboembolizam
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